Diagnostics
MindBio Therapeutics Adds AI-Powered Fatigue Detection to Voice-Based Diagnostics Platform
MindBio Therapeutics expands its AI voice diagnostics platform with fatigue recognition technology for high-risk industries, with commercial testing expected in late Q2 2026.
MindBio Therapeutics Advances AI Voice-Based Intoxication Detection Amid Growing Real-Time Diagnostics Market
MindBio Therapeutics is developing an AI-driven voice analysis platform to detect drug and alcohol intoxication in real time, targeting workplace safety, healthcare, and public safety markets as traditional testing methods face limitations.
AI and Multi-Omics Converge: Cardio Diagnostics Targets Earlier, More Precise Cardiac Insights
Cardio Diagnostics Holdings is leveraging artificial intelligence and multi-omic biomarkers to improve early detection and personalized treatment of cardiovascular disease, addressing a critical gap in traditional risk assessment.
Cardio Diagnostics Harnesses AI and Biomarkers to Combat Heart Disease Burden
Cardio Diagnostics Holdings is advancing early detection of cardiovascular disease using an AI-powered platform that analyzes epigenetic and genetic biomarkers from a simple blood sample, addressing the leading cause of death in the U.S.
VolitionRx Achieves Technical Milestone in Sepsis Detection with Finger-Prick Prototype
VolitionRx announced a prototype that can detect nucleosomes in capillary blood from sepsis patients, potentially enabling point-of-care testing and expanding access in regions with limited lab infrastructure.
MindBio Therapeutics Develops AI-Powered Voice Analysis for Non-Invasive Drug and Alcohol Detection
MindBio Therapeutics is launching an AI-driven voice analysis technology to detect impairment, targeting a growing $4.2 billion testing market and offering a less invasive alternative to traditional methods.
Cardio Diagnostics Leverages AI and Multi-Omic Biomarkers to Combat Cardiovascular Disease
Cardio Diagnostics Holdings is advancing AI-driven blood tests for earlier, more personalized detection and management of cardiovascular disease, addressing the leading cause of death in the U.S.
Cardio Diagnostics Leverages AI and Genomics to Revolutionize Cardiovascular Disease Detection
Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing AI-powered solutions using simple blood tests to detect and manage cardiovascular disease, addressing the leading cause of death in the US.
Cardio Diagnostics' AI Platform Aims to Transform Cardiovascular Risk Assessment
Cardio Diagnostics Holdings uses artificial intelligence and multi-omic data from a simple blood draw to provide personalized cardiovascular risk assessments, potentially shifting heart health diagnostics from population-based models to precise, individualized insights.
Novel Urine Test May Predict Bladder Cancer Treatment Response
Researchers have developed a urine test that detects tumor DNA to predict residual bladder cancer after surgery and assess immunotherapy effectiveness.
Cardio Diagnostics Holdings Gains Attention for AI-Driven Cardiovascular Platform
Cardio Diagnostics Holdings is highlighted as a company to watch due to its AI-powered approach to cardiovascular disease prevention, detection, and management, integrating epigenetics and genetics for personalized insights.
Aditxt Subsidiary's Protein Analysis Platform Shows Promise in Breast Cancer Treatment Study
A study published in npj Precision Oncology found that Ignite Proteomics' protein analysis platform provided more predictive insight into metastatic breast cancer treatment outcomes than traditional methods, potentially improving treatment selection.
Cardio Diagnostics Holdings Leverages AI and Epigenetics for Advanced Cardiovascular Disease Management
Cardio Diagnostics Holdings is advancing cardiovascular disease prevention and detection through an AI-driven platform that integrates genetics and epigenetics to provide personalized insights.
Molecular Testing Gains Importance in Complex CNS Cancer Diagnosis and Treatment
Molecular analysis is becoming crucial for identifying and treating complex central nervous system tumors, which traditional methods often miss, with companies like CNS Pharmaceuticals advancing targeted drug development.
Utah Governor and BioUtah Recognize Co-Diagnostics Following Saudi Arabia Joint Venture
Co-Diagnostics' expansion into Saudi Arabia through a new joint venture demonstrates Utah's growing influence in global life sciences and represents significant international market penetration for local diagnostic technology.
Combined Biomarker Analysis Reveals Triple Heart Attack Risk in High-Risk Individuals
A new study shows that analyzing three specific biomarkers together can identify individuals with nearly triple the risk of heart attack, potentially enabling earlier intervention and personalized prevention strategies.
FDA Clears First 4-in-1 Home Test for RSV, Flu, and COVID Detection
ACON Laboratories has received FDA clearance for the first over-the-counter home test that simultaneously detects RSV, influenza A, influenza B, and COVID-19, representing a significant advancement in consumer respiratory health monitoring.
Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic
Aditxt's subsidiary Pearsanta has begun enrolling patients in a clinical study for a novel blood-based endometriosis test that could provide earlier, non-invasive detection compared to current surgical methods.
New Melanoma Test Shows Three-Fold Improvement in Predicting Lymph Node Metastasis Risk
The Merlin CP-GEP test accurately stratifies melanoma patients by sentinel node metastasis risk, potentially reducing unnecessary surgical procedures through improved personalized care.
AXIM Biotechnologies Secures Exclusive South Korean Distribution for TearScan Diagnostic Tests
AXIM Biotechnologies has partnered with VisionPlus Corp. to exclusively distribute its TearScan diagnostic tests in South Korea, expanding access to advanced ocular diagnostics in a market experiencing rising dry eye disease cases.
FDA Approves One-Minute HIV Self-Test in Major Public Health Advancement
The FDA's approval of bioLytical's INSTI® HIV Self Test, which provides results in 60 seconds, represents a significant step toward reducing undiagnosed HIV cases and supporting national goals to end the HIV epidemic by making testing more accessible and private.
AXIM Biotechnologies Partners with JK Medical to Expand Ocular Diagnostic Access Across Latin America
AXIM Biotechnologies has entered an exclusive licensing agreement with JK Medical to distribute its TearScan® diagnostic tests across seven Latin American countries, addressing critical unmet needs in dry eye disease diagnosis through rapid point-of-care testing.
VolitionRx Partners with Hologic to Expand Access to Epigenetic Testing Services
VolitionRx has entered a co-marketing agreement with Hologic to promote its Nu.Q® Discover epigenetic profiling service, expanding access to pharmaceutical and academic researchers in a market valued at $200 million annually.
Creative Biolabs Expands IVD Capabilities with Integrated Protein and Nucleic Acid Detection
Creative Biolabs has enhanced its in vitro diagnostics services by integrating protein and nucleic acid detection technologies, offering researchers more comprehensive biomarker analysis for early disease detection and complex condition research.
LabConnect Appoints Industry Veteran Bill Finger to Lead Global Strategic Services
LabConnect has appointed Bill Finger as Senior Vice President of Global Strategic Services, bringing over 25 years of diagnostics and clinical research expertise to enhance the company's capabilities in complex clinical trials.
Plus Therapeutics Subsidiary CNSide Diagnostics Achieves CLIA Accreditation for CNS Cancer Testing Lab
CNSide Diagnostics has received CMS accreditation for its clinical laboratory, enabling broader patient access and insurance coverage for its cerebrospinal fluid assay platform used in central nervous system cancer detection.
Streamline Scientific Launches Enhanced PCR Reporting Service to Combat Antibiotic Misuse in UTI Treatment
Streamline Scientific's new PCR reporting service integrates clinical guidelines directly into test results to help physicians make more informed antibiotic prescribing decisions for urinary tract infections, addressing the critical issue of antimicrobial resistance.
VolitionRx Partners with Werfen to Advance Diagnostic Testing for Antiphospholipid Syndrome
VolitionRx has signed an agreement with Werfen to evaluate its Nu.Q NETs assay for improved detection and monitoring of antiphospholipid syndrome, potentially transforming diagnosis and management for millions of patients worldwide.
MyBioSource Launches Validated Anti-CALB2 Antibody for Neuroscience Research
MyBioSource has introduced a validated sheep anti-rat calretinin polyclonal antibody that enables advanced research into calcium signaling, neuroprotection, and neurodegeneration across multiple species.
Biotech Merger Creates OSPRI to Revolutionize Infectious Disease Testing with $30M Backing
The merger of Community Direct DX, Scienetix, and Advanta Genetics R&D into OSPRI creates a vertically-integrated molecular testing platform that reduces PCR testing costs by 20-50% and time by 50-70%, addressing critical accessibility barriers in healthcare diagnostics.